Evidence map›Paper›PMID 20092323›Full record

ArticleJournal of medicinal chemistry2010

Single agents with designed combination chemotherapy potential: synthesis and evaluation of substituted pyrimido[4,5-b]indoles as receptor tyrosine kinase and thymidylate synthase inhibitors and as antitumor agents.

Aleem Gangjee, Nilesh Zaware, Sudhir Raghavan, Michael Ihnat, Satyendra Shenoy, Roy L Kisliuk

Open access · greenAbstract read
In one paragraph

Article in Journal of medicinal chemistry, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 50 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Discovery of potent and selective inhibitors ofACS medicinal chemistry letters · 2013
    Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Aleem GangjeeDivision of Medicinal Chemistry, Graduate School of Pharmaceutical Sciences, Duquesne University, 600 Forbes Avenue, Pittsburgh, Pennsylvania 15282, USA. gangjee@duq.edu
Nilesh Zaware
Sudhir Raghavan
Michael Ihnat
Satyendra Shenoy
Roy L Kisliuk
Duquesne University · USUniversity of Oklahoma Health Sciences Center · USTufts University · US

Funding

Single Agents with Designed Combination Chemotherapy PotentialR01CA136944 · NCI · DUQUESNE UNIVERSITY · PI GANGJEE, ALEEM · 2009 to 2010
$612k
NCI NIH HHS CA136944NCI NIH HHS R01 CA136944
6 · The paper itself

Abstract

Combinations of antiangiogenic agents (AAs) with cytotoxic agents have shown significant promise in cancer treatment, and several such clinical trials are currently underway. We have designed, synthesized, and evaluated two compounds that each inhibit vascular endothelial growth factor receptor-2 (VEGFR-2) and platelet-derived growth factor receptor-beta (PDGFR-beta) for antiangiogenic effects and also inhibit human thymidylate synthase (hTS) for cytotoxic effects in single agents. The synthesis of these compounds involved the nucleophilic displacement of the common intermediate 5-chloro-9H-pyrimido[4,5-b]indole-2,4-diamine with appropriate benzenethiols. The inhibitory potency of both these single agents against VEGFR-2, PDGFR-beta, and hTS is better than or close to standards. In a COLO-205 xenograft mouse model, one of the analogs significantly decreased tumor growth (tumor growth inhibition (TGI) = 76% at 35 mg/kg), liver metastases, and tumor blood vessels compared with a standard drug and with control and thus demonstrated potent tumor growth inhibition, inhibition of metastasis, and antiangiogenic effects in vivo. These compounds afford combination chemotherapeutic potential in single agents.

Indexed as

Angiogenesis InhibitorsAnimalsAntineoplastic AgentsCell Line, TumorChick EmbryoDrug Screening Assays, AntitumorHumansIndolesMaleMiceMice, NudeModels, MolecularNeoplasm TransplantationPyrimidinesReceptor, Platelet-Derived Growth Factor betaStructure-Activity RelationshipAngiogenesis InhibitorsAntineoplastic AgentsIndolesPyrimidinesReceptor, Platelet-Derived Growth Factor betaSulfhydryl CompoundsThymidylate SynthaseVascular Endothelial Growth Factor Receptor-2

Identifiers

PMID20092323
PMCPMC2825747
OpenAlexW2052281047

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.